CN108025003B - 前额叶皮质处理病症，步态和肢体障碍治疗 - Google Patents

前额叶皮质处理病症，步态和肢体障碍治疗 Download PDF

Info

Publication number
CN108025003B
CN108025003B CN201680052229.7A CN201680052229A CN108025003B CN 108025003 B CN108025003 B CN 108025003B CN 201680052229 A CN201680052229 A CN 201680052229A CN 108025003 B CN108025003 B CN 108025003B
Authority
CN
China
Prior art keywords
gait
methylphenidate
disorder
subject
limb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680052229.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN108025003A (zh
Inventor
布鲁斯·罗斯曼
基拉·卡普兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kira Kaplan
Original Assignee
GILROSE PHARMACEUTICALS LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/793,829 external-priority patent/US9307942B2/en
Priority claimed from US15/075,375 external-priority patent/US9682073B2/en
Application filed by GILROSE PHARMACEUTICALS LLC filed Critical GILROSE PHARMACEUTICALS LLC
Publication of CN108025003A publication Critical patent/CN108025003A/zh
Application granted granted Critical
Publication of CN108025003B publication Critical patent/CN108025003B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201680052229.7A 2015-07-08 2016-06-14 前额叶皮质处理病症，步态和肢体障碍治疗 Active CN108025003B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US14/793,829 US9307942B2 (en) 2011-05-19 2015-07-08 Treatment for cerebral palsy gait impairment
US14/793,829 2015-07-08
US14/881,516 2015-10-13
US14/881,516 US9333198B2 (en) 2011-05-19 2015-10-13 Treatment for cerebral palsy gait impairment
US14/971,325 2015-12-16
US14/971,325 US9408838B2 (en) 2011-05-19 2015-12-16 Treatment for cerebral palsy gait impairment
US15/075,375 2016-03-21
US15/075,375 US9682073B2 (en) 2011-05-19 2016-03-21 Pre-frontal cortex processing disorder gait and limb impairments treatment
PCT/US2016/037367 WO2017007577A1 (en) 2015-07-08 2016-06-14 Pre-frontal cortex processing disorder, gait and limb impairment treatment

Publications (2)

Publication Number Publication Date
CN108025003A CN108025003A (zh) 2018-05-11
CN108025003B true CN108025003B (zh) 2021-07-13

Family

ID=57686013

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680052229.7A Active CN108025003B (zh) 2015-07-08 2016-06-14 前额叶皮质处理病症，步态和肢体障碍治疗

Country Status (6)

Country Link
EP (1) EP3319603B1 (enExample)
JP (2) JP6930969B2 (enExample)
CN (1) CN108025003B (enExample)
CA (1) CA2991529C (enExample)
MX (1) MX2017016910A (enExample)
WO (1) WO2017007577A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017007577A1 (en) * 2015-07-08 2017-01-12 Gilrose Pharmaceuticals, Llc Pre-frontal cortex processing disorder, gait and limb impairment treatment

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2157880A (en) 1937-01-22 1939-05-09 Electrical Res Prod Inc Recording system
US2507631A (en) 1944-01-19 1950-05-16 Ciba Pharm Prod Inc Pyridine and piperidine compounds and process of making same
US4145083A (en) 1977-06-17 1979-03-20 Urban Frank K Therapeutic chair for cerebral palsy child
US4844075A (en) 1984-01-09 1989-07-04 Pain Suppression Labs, Inc. Transcranial stimulation for the treatment of cerebral palsy
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US6355656B1 (en) 1995-12-04 2002-03-12 Celgene Corporation Phenidate drug formulations having diminished abuse potential
US5908850A (en) 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
US6121261A (en) 1997-11-19 2000-09-19 Merck & Co., Inc. Method for treating attention deficit disorder
RU2185106C1 (ru) 2001-07-12 2002-07-20 Свадовский Александр Игоревич Способ нейрохирургического лечения детского церебрального паралича
US8952895B2 (en) * 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
JP4943845B2 (ja) * 2003-09-17 2012-05-30 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ サリドマイド類似体
WO2005063248A1 (en) 2003-12-22 2005-07-14 Sepracor Inc. Modafinil combination therapy for improving sleep quality
US20050182097A1 (en) 2003-12-30 2005-08-18 Zeldis Jerome B. Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
WO2006076681A2 (en) * 2005-01-13 2006-07-20 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
AU2006216646B2 (en) * 2005-02-23 2012-05-31 Prexa Pharmaceuticals, Inc. Dopamine transporter inhibitors for use in treatment of movement disorders and other cns indications
EP2032987B1 (en) * 2006-05-22 2016-02-24 The Board of Trustees of The Leland Stanford Junior University Pharmacological treatment of cognitive impairment
EP1985276A1 (en) 2007-04-26 2008-10-29 Merz Pharma GmbH & Co. KGaA Treatment of movement disorders by a combined use of a chemodenervating agent and automated movement therapy
US20110270345A1 (en) 2007-08-11 2011-11-03 Johns Hopkins University Focal noninvasive stimulation of the sensory cortex of a subject with cerebral palsy
CN102170874A (zh) * 2008-08-06 2011-08-31 高思福斯中心（控股）有限公司 治疗精神病学障碍的组合物和方法
US20120245201A1 (en) * 2009-07-23 2012-09-27 Markowitz John S Isopropylphenidate for Treatment of Attention-Deficit/Hyperactivity Disorder and Fatigue-Related Disorders and Conditions
EP2521546A4 (en) 2010-01-07 2013-06-26 Vivus Inc TREATMENT OF THE OBSTRUCTIVE SLEEP APNEO SYNDROME COMBINED WITH ANTIBODY ANTIBODY AND AN ADDITIONAL ACTIVE SUBSTANCE
CN102792513A (zh) * 2010-03-01 2012-11-21 波士顿电力公司 具有平均温度及热点回授之热感测器装置
EP2544688B1 (en) * 2010-03-02 2016-09-07 President and Fellows of Harvard College Methods and compositions for treatment of angelman syndrome
US8287903B2 (en) 2011-02-15 2012-10-16 Tris Pharma Inc Orally effective methylphenidate extended release powder and aqueous suspension product
US8883815B2 (en) 2011-05-19 2014-11-11 Gilrose Pharmaceuticals, Llc Treatment for cerebral palsy impaired speech in children
US9682073B2 (en) * 2011-05-19 2017-06-20 Gilrose Pharmaceuticals, Llc Pre-frontal cortex processing disorder gait and limb impairments treatment
US20140163070A1 (en) 2012-05-17 2014-06-12 Bruce Roseman Treatment for cerebral palsy impaired speech in children
WO2012158892A2 (en) 2011-05-19 2012-11-22 Bruce Roseman A method of treating apraxia of speech in children
KR20130016127A (ko) * 2011-08-04 2013-02-14 의료법인 성광의료재단 외상성 뇌손상의 치료
AU2012348505B2 (en) * 2011-12-08 2016-10-06 APOS Medical Assets Ltd Device and methods for treating neurological disorders
EP2705841A1 (en) * 2012-09-05 2014-03-12 Pharnext Combinations of nootropic agents for treating cognitive dysfunctions
US9305307B2 (en) * 2013-07-15 2016-04-05 Google Inc. Selecting content associated with a collection of entities
US20150133667A1 (en) * 2013-11-08 2015-05-14 Noramco, Inc. Process for the preparation of methylphenidate and pharmaceutical salts thereof
WO2017007577A1 (en) 2015-07-08 2017-01-12 Gilrose Pharmaceuticals, Llc Pre-frontal cortex processing disorder, gait and limb impairment treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Methylphenidate for cerebral palsy with choreoathetosis;Boogerd, W et al.;《ANNALS OF INTERNAL MEDICINE》;20000321;第132卷(第6期);第510页 *

Also Published As

Publication number Publication date
JP7350794B2 (ja) 2023-09-26
JP2018521127A (ja) 2018-08-02
EP3319603A1 (en) 2018-05-16
EP3319603B1 (en) 2021-11-17
EP3319603A4 (en) 2019-03-13
JP2021088571A (ja) 2021-06-10
WO2017007577A1 (en) 2017-01-12
CN108025003A (zh) 2018-05-11
MX2017016910A (es) 2018-08-15
CA2991529C (en) 2021-01-05
CA2991529A1 (en) 2017-01-12
JP6930969B2 (ja) 2021-09-01

Similar Documents

Publication Publication Date Title
US9333198B2 (en) Treatment for cerebral palsy gait impairment
NZ745778A (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
Furr-Stimming et al. Spasticity and intrathecal baclofen
EP2667869A1 (en) Use of potassium channel blockers to treat cerebral palsy
Duffell et al. Facilitatory effects of anti-spastic medication on robotic locomotor training in people with chronic incomplete spinal cord injury
US9682073B2 (en) Pre-frontal cortex processing disorder gait and limb impairments treatment
KR20170131543A (ko) 근위축성 측삭 경화증을 치료하기 위한 비오틴
JP7350794B2 (ja) 前頭前皮質プロセシング疾患、歩行及び四肢障害の治療
US11102953B2 (en) Pre-frontal cortex processing disorder speech, gait and limb impairments treatment
CA3091353A1 (en) Therapeutic agents for treating restless legs syndrome
KR20190122664A (ko) 헌팅턴 병 치료를 위한 PPARγ효현제
RU2594252C1 (ru) Способ реабилитации больных алкогольной полинейропатией
Walton Management of patients with spasticity-a practical approach
Umale et al. Ayurveda management of Kampavata with special reference to Parkinson’s disease-A single case study
Yadav et al. Integrated treatment approach to Miller Fisher syndrome, a variant of Guillain-Barre syndrome–A case report
JP2019517516A (ja) Ｓｍａの新規な処置
JP6749022B2 (ja) 自己免疫疾患治療剤
TW202539621A (zh) 用於治療巴金森氏症的治療劑
Gelber Management of spasticity
WO2025163129A1 (en) Acetyl-leucine for treating parkinson´s disease
Meythaler et al. Use of 4-aminopyridine for motor weakness due to Charcot-Marie-Tooth hereditary motor sensory neuropathy
HK1262519A1 (en) New treatment of sma
Spiegelhalder et al. Movement disorders in the elderly
Spiegelhalder et al. Sleep disorders in the elderly Movement disorders in the elderly

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20251105

Address after: New York, USA

Patentee after: Kira Kaplan

Country or region after: U.S.A.

Address before: New York, USA

Patentee before: GILROSE PHARMACEUTICALS, LLC

Country or region before: U.S.A.